Chief Judge David R. Herndon Names Tor Hoerman as Leader in Pradaxa Litigation
Tor Hoerman is thrilled to be appointed as leader in the national litigation on behalf of people injured from use of Pradaxa, the blockbuster blood-thinning medicine manufactured by Boehringer Ingelheim.
Online PR News – 04-October-2012 –Chief Judge David R. Herndon of the Southern District of Illinois, the judge presiding over the federal Pradaxa litigation, has announced the plaintiffs’ leadership counsel who will oversee the interests of the plaintiffs in the Pradaxa litigation (MDL 2385). TorHoerman Law is proud to announce that Tor Hoerman has been named as Co-Lead Counsel and Steven Davis has been named as Co-Liason Counsel. Tor and Steven look forward to cooperating with attorneys on both sides of the litigation in order to advance the litigation in a timely manner.
Pradaxa is a blood-thinning medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation. Although Pradaxa has only been on the market for two years, there have already been 17,254 reports of adverse effects where Pradaxa was the primary suspect. According to the AdverseEvents drug report for Pradaxa, death has resulted in 11% of these adverse event cases. Despite current questions about bleeding risks, Pradaxa sales hit blockbuster status in 2012.
TorHoerman Law continues to talk to families who have experienced the life altering injury or death of a loved one as a result of Pradaxa use and offers anyone that would like to explore their legal rights a no-cost, no-obligation Pradaxa lawsuit case review.
Chief Judge Herndon indicated that he anticipates trying the first case related to these life-altering side effects in approximately eighteen to twenty four months. Given the seriousness of the allegations and the impact this litigation can have on doctors that are currently prescribing Pradaxa, the plaintiffs’ leadership team is prepared to use their resources to advance the litigation efficiently. As of today, about 130 cases are on file with the Southern District of Illinois. We anticipate those numbers will continue to rise.
In addition to appointing Tor and Steven, the court has appointed additional exceptionally highly qualified lawyers in the positions of co-lead counsel as well as executive and steering committees, details of which can be found at the following link - Case Management Order Number 4, In Re:Pradaxa (Dabigatran Etexilate) Products Liability Litigation
About TorHoerman Law
The lawyers at TorHoerman Law have proudly taken leadership roles in several national litigation efforts in addition to their current role as leaders in Pradaxa. These cases include Gadolinium, Zelnrom, Zyprexa, Yaz, Oxycontin, Bextra, Vioxx, HRT, Actos, Transvaginal mesh and many other national efforts.
The best lawyers can only achieve great results when they surround themselves with great people. At the heart of TorHoerman Law LLC, is our veteran staff of investigators, medical staff, secretaries, paralegals and case support personnel who are skilled at providing the exceptional personal attention that each individual client deserves.
Copyright 2014 Online PR Media | PO Box 5043 | La Quinta, CA 92248